Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label SOF/VEL/VOX in prior Gilead HCV study participants
2017-000179-98Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sofosbuvir, velpatasvir and voxilaprevir in chronic hepatitis C (CHC) and hepatitis C virus infection, sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Apr 2017; status: completed.
02
Drugs
sofosbuvirvelpatasvirvoxilaprevir
03
Conditions
chronic hepatitis C (CHC)hepatitis C virus infection
Beyond the preview
Go deeper on 2017-000179-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000179-98.